Agenus (NASDAQ:AGEN) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of Agenus (NASDAQ:AGEN) from a sell rating to a hold rating in a research report released on Tuesday morning, ValuEngine reports.

Separately, BidaskClub upgraded Agenus from a sell rating to a hold rating in a report on Monday, November 11th.

Shares of AGEN traded down $0.02 during trading hours on Tuesday, hitting $3.72. 1,454,800 shares of the company were exchanged, compared to its average volume of 1,356,839. Agenus has a one year low of $1.95 and a one year high of $4.01. The firm has a fifty day simple moving average of $2.81 and a 200-day simple moving average of $2.77. The company has a market capitalization of $517.85 million, a PE ratio of -2.58 and a beta of 1.84.

Agenus (NASDAQ:AGEN) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.05. The company had revenue of $19.94 million for the quarter, compared to the consensus estimate of $15.60 million. Equities analysts anticipate that Agenus will post -0.96 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in Agenus by 28.3% during the second quarter. JPMorgan Chase & Co. now owns 28,741 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 6,332 shares in the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in shares of Agenus in the second quarter worth about $40,000. Acadian Asset Management LLC increased its stake in shares of Agenus by 227.7% in the second quarter. Acadian Asset Management LLC now owns 195,172 shares of the biotechnology company’s stock worth $586,000 after purchasing an additional 135,617 shares during the period. Alps Advisors Inc. bought a new position in shares of Agenus in the second quarter worth about $843,000. Finally, Vanguard Group Inc. increased its stake in shares of Agenus by 16.7% in the second quarter. Vanguard Group Inc. now owns 5,540,211 shares of the biotechnology company’s stock worth $16,620,000 after purchasing an additional 793,180 shares during the period. Institutional investors own 35.25% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Featured Article: What is the Hang Seng index?  

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.